Risk Stratification in Metabolic Dysfunction-Associated Steatohepatitis: Early Versus Late Fibrosis

Description

Experts examine the importance of fibrosis staging in the risk assessment and management of metabolic-associated steatohepatitis (MASH). The session explores the clinical implications of focusing on early-stage versus late-stage fibrosis; evaluates the role of advanced diagnostic tools in stratifying risk; and reviews how targeted approaches can improve patient outcomes. This community conversation aims to impart a deeper understanding of how to prioritize interventions based on fibrosis severity and emerging evidence.

Journey Maps

Presentations

3:45 PM - 4:05 PM
Nov 10 2025
San Diego, CA

Risk Stratification for Early Metabolic Dysfunction-Associated Steatohepatitis

Alina M. Allen, MD, Presenter
MASLD
4:05 PM - 4:25 PM
Nov 10 2025
San Diego, CA

Risk Stratification for Late Metabolic Dysfunction-Associated Steatohepatitis

Ian A Rowe, PhD, Presenter
MASLD
4:20 PM - 4:20 PM
Nov 10 2025
San Diego, CA

Panel Discussion

Amreen Dinani, MD FRCPC, Panelist
MASLD

Objectives

  • Review the impact of early-stage versus late-stage fibrosis on disease progression, patient management, and prognosis in MASH.
  • Assess advanced diagnostic tools and techniques, including noninvasive technologies, and their application in stratifying patients by fibrosis stage.
  • Identify tailored risk stratification approaches to optimize treatment plans and resource allocation based on fibrosis stage and patient needs.